Indian Pharma Giant Cipla Injects EUR 3 Million into German Biotech Firm Ethris

Cipla, an Indian pharmaceutical firm, revealed that its fully-owned UK subsidiary, Cipla (EU), plans to invest an extra EUR 3 million in Ethris GmbH. Ethris is a global frontrunner in the direct delivery of mRNAs to the respiratory system. This new investment, structured as a convertible loan, aims to boost Cipla’s engagement in the mRNA sector. Previously, Cipla had invested EUR 15 million in Ethris in 2022. The additional funding underscores Cipla’s trust in Ethris’s unique mRNA technology and its promise for patients in developing markets.

Cipla and Ethris are collaborating on a long-term strategic partnership to accelerate the development of innovative mRNA-based therapies. The COVID-19 pandemic highlighted the significance of mRNA vaccines, with the first regulatory approvals for SARS-CoV-2. mRNA-based medicines hold significant promise for various applications, including protein replacement therapies, therapeutic cancer vaccines and infectious disease vaccines.

Umang Vohra, Managing Director & Global Chief Executive Officer of Cipla, said in a statement, “At Cipla, we strive to dial-up our focus and investment towards innovative modalities and bring new age therapies to emerging countries, including India. The follow-on investment in Ethris will help get cutting-edge healthcare solutions like mRNA-based therapies to the Global South. As we lead Cipla ahead, we will continue to work towards building an innovative future and build brands that reinforce our ethos of ‘caring for life’.”

Dr Carsten Rudolph, CEO of Ethris, added, “The additional investment by Cipla further validates the broad potential of our platform and Ethris’ innovative approaches to developing respiratory RNA-based medicines. We deeply value this ongoing relationship to bring effective solutions to developing countries. The capital will enable us to continue advancing our pipeline and we look forward to providing an update on our lead program in the near term”, said De Carsten Rudolph, CEO of Ethris.